Ablexis
Latest round
- Series A
Last raised
- Jun 2010
Total raised
- $12M
Investors
- 2
About Ablexis
Ablexis, LLC is engaged in developing a transgenic mouse platform designed for therapeutic antibody discovery. The company is headquartered in San Francisco, US. Larry Green is the founder and CEO, bringing experience from prior ventures in the biotech sector.Ablexis specializes in a next-generation transgenic mouse platform designed specifically for the discovery of therapeutic antibodies. Their core product, the AlivaMab-X Mouse, is engineered to deliver enhanced immune responses, facilitating a more efficient antibody discovery process. The platform is utilized primarily by biotechnology and pharmaceutical companies engaged in developing novel therapeutics, aiming to address critical healthcare needs.Ablexis operates on a revenue model structured around partnerships and licensing agreements with biopharmaceutical companies. Clients engage with Ablexis through tailored licensing options that allow them to integrate the AlivaMab-X Mouse platform into their research and development workflows. The company seeks to introduce enhancements to the AlivaMab-X Mouse platform by late 2021, targeting biotechnology firms in emerging markets, particularly in Asia and Europe. The focus will be on increasing partnerships with research institutions while enhancing the capabilities of their existing offerings, ensuring alignment with the growing demand for innovative therapeutic solutions.
Who invested in Ablexis
2 investors across 1 round
See all investors in Ablexis
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Jun 2, 2010
Amount
$12M
Investors
Questions about Ablexis
Who invested in Ablexis?
Ablexis has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Ablexis raised?
Ablexis has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Ablexis last raise money?
Ablexis's most recent round on record is a Series A, in Jun 2010.
What does Ablexis do?
Ablexis, LLC is engaged in developing a transgenic mouse platform designed for therapeutic antibody discovery.
Where is Ablexis headquartered?
Ablexis is headquartered in San Francisco, US.
Which VCs invest in companies like Ablexis?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Ablexis's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Ablexis? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.